Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 6:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 17,811 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiration Rate Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Early Immune Responses to Inactivated Influenza Vaccine: a Pilot Study

NCT01522248
View directory record Official record
Conditions
Influenza Virus Vaccine
Interventions
Trivalent Inactivated Influenza vaccine
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine

NCT05743335
View directory record Official record
Conditions
COVID-19, Infectious Disease
Interventions
JCXH-221, Placebo
Biological · Other
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
4
States / cities
Hallandale, Florida • Savannah, Georgia • Lincoln, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Not applicable Interventional Results available

Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions

NCT03938324
View directory record Official record
Conditions
Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis
Interventions
PiCASO Intervention Group, Sham Comparator: Attention Control Group
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 22 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 18, 2026, 6:21 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

NCT00500123
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
Alpha-1 Antitrypsin Genotype
Procedure
Lead sponsor
University of Florida
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2050
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

FLU-VACS Comparative Study in Adults

NCT00133523
View directory record Official record
Conditions
Influenza
Interventions
Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
2,349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
6
States / cities
Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

NCT01429259
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions
meropenem
Drug
Lead sponsor
Joseph Kuti
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Yogic Breathing and Guided Meditation for Long Covid Symptoms

NCT05139979
View directory record Official record
Conditions
COVID-19, Stress, Shortness of Breath
Interventions
Breathing and Wellness Webinar, Routine Daily Activity
Behavioral · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis

NCT00001761
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Interleukin-10
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00726986
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, sorafenib tosylate
Drug
Lead sponsor
Afshin Dowlati, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
New York, New York • Cleveland, Ohio • Mayfield Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 4 Interventional Results available

Acute Cough Study In Children

NCT01257542
View directory record Official record
Conditions
Common Cold, Infections, Upper Respiratory Tract
Interventions
Dextromethorphan, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 11 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Pinellas Park, Florida • Indianapolis, Indiana • Gresham, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional

Exploratory Study for Allergy Relief Onset

NCT02722083
View directory record Official record
Conditions
Rhinitis, Allergic
Interventions
Chlorpheniramine maleate (BAY X002134), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 2 Interventional Results available

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

NCT02819856
View directory record Official record
Conditions
Ototoxicity
Interventions
Placebo, SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 1 Interventional

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

NCT07121829
View directory record Official record
Conditions
Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
Interventions
Tovorafenib, Tovorafenib Drug: Pimasertib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 18, 2026, 6:21 AM EDT
Completed No phase listed Observational

Breathing Cycle Biofeedback During Computed Tomography Procedures

NCT00059137
View directory record Official record
Conditions
Needle Biopsy, CAT Scan, X-Ray
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age

NCT06641180
View directory record Official record
Conditions
Influenza
Interventions
High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
50 Years to 64 Years
Enrollment
1,180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
20
States / cities
Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementing Pathways to Improve Pediatric Asthma Care

NCT03736603
View directory record Official record
Conditions
Asthma
Interventions
PIPA Intervention Bundle 1, PIPA Intervention Bundle 2
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

NCT01875003
View directory record Official record
Conditions
Asthma
Interventions
Lebrikizumab, Placebo, Standard of Care
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 17 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Mission Viejo, California • Stockton, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 6:21 AM EDT
Recruiting Phase 3 Interventional

Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea

NCT07332442
View directory record Official record
Conditions
Sleep Apnea, Obstructive Sleep Apnea
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
North Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 4 Interventional

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

NCT00058929
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
treprostinil sodium
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 2 Interventional

Safety of Ramelteon in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease

NCT00672802
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
Ramelteon and Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
21 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
Birmingham, Alabama • Santa Monica, California • Miami Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Results available

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

NCT01600053
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide
Drug
Lead sponsor
Thomas Kipps
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 18, 2026, 6:21 AM EDT
Completed Phase 3 Interventional

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT02125253
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Mometasone Furoate Nasal Spray, 50 mcg, Nasonex Nasal Spray, 50 mcg, Placebo Nasal Spray
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older
Enrollment
811 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 18, 2026, 6:21 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

NCT04329923
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine Sulfate 400 mg twice a day, Hydroxychloroquine Sulfate 600 mg twice a day, Hydroxychloroquine Sulfate 600 mg once a day, Placebo oral tablet
Drug
Lead sponsor
Ravi Amaravadi, MD
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 18, 2026, 6:21 AM EDT
Not listed Early Phase 1 Interventional

Evaluating Efficacy of Smart Device in Assisting With Inhaler Technique and Adherence

NCT04250779
View directory record Official record
Conditions
Asthma, Adherence, Medication, Childhood Asthma
Interventions
CapMedic smart inhaler device, Video-based guidance
Device · Behavioral
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
8 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 18, 2026, 6:21 AM EDT